Drug Approval | October 16, 2024
Enhertu approved in China as first HER2-directed therapy for patients with HER2-mutant metastatic NSCLC
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
Showcases specialty and sustainable materials for healthcare at Medtec China 2024
Approval based on MIRACLE Phase III trial demonstrating a significant and clinically meaningful reduction in asthma exacerbations and improvement in asthma symptom control
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
_256_384.jpg)
€ 6.6 million investment at Nantong site expands production capabilities for cell culture media
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
Approval based on a separate phase III trial among Chinese patients reinforcing mepolizumab’s efficacy and safety data
Innovent will supply sintilimab for the collaborated clinical trial
Furthering cell therapy ambition across oncology and autoimmune diseases
Subscribe To Our Newsletter & Stay Updated
